Table 3 Dose and Safety Margins (*excessive mitotic figures without other features of frank malignancy)
Author | Number of cases (patients with RT) | WHO Grade | Mean Dose (if not otherwise specified) [Gy] | CTV-Margin [mm] | PTV-Margin [mm] | Local control rate (at respective timepoint) |
|---|---|---|---|---|---|---|
Aboukais et al. [40] | 167 (27) | II | 53.8 | 10–20 | 5 | Median PFS 8.2y |
Hug et al.[41] | 31 (31) | II + III | 58 | Not mentioned | Not mentioned | 46.5% (no time mentioned) |
Park et al.[42] | 83 (27) | II | median61.2 | 15 | 3 | 58.7% (no time mentioned) |
Kumar et al. [14] | 37 (37) | II + III | 54 | 10–20 | 5 | 58% [°II]; 20% [°III] (5y) |
Boskos et al.[43] | 24 (24) | II + III | 65 | 5–20 | Not mentioned | 46.7% (8y) |
Aghi et al.[44] | 108 (38) | II | 60.2 | 10 in total | 100% (3.1y) | |
Dziuk et al.[45] | 48 (19) | III | 54 | 30–40 in total | 25% (5y) | |
Press et al. [35] | 54 (54) | II | 59.4 | 5 | 3 | 74% (3y) |
Choi et al. [29] | 114 (89) | II + III | 60 | 10–20 | Not mentioned | 68% (5y) |
Condra et al. [16] | 262 (21 (S + RT) / 7(RT alone)) | I-III | 53.3 (post-op) / 51.7 (RT alone) | 20 in total | 78% (15y) / 86% (5y) | |
Glaholm et al.[46] | 186 (43) | II + III and aggressive I* | Range 50–55 | Not mentioned | Not mentioned | 78% (5y) |
Milosevic et al. [28] | 59 (59) | II + III | 50 | 30–40 in total | 34% (no time mentioned) | |
Goldsmith et al. [31] | 140 (140, 23 of malign type) | I-III | 54 | 10–30 in total | 89% (5y) | |
Goyal et al. [27] | 22 (8) | II | 54 | Not mentioned | Not mentioned | 71% (5y) |
Adeberg et al.[47] | 85 (84) | II + III | 57.6 | 10–20 | 1–5 | 50% [°II]; 13% [°III] (5y) |
Engenhart-Cabillic [48] et al. | 16 (7) | II + III | 55.5–60 | Not mentioned | Not mentioned | 62.5% (2.3y) |
Pasquier et al.[49] | 119 (119) | II + III | 54.6 | Not mentioned | Not mentioned | 62% [°II]; 48% [°III] (5y) |
Katz et al. [32] | 36 (36) | II + III | 55–60 | Not mentioned | Not mentioned | 45% (5y) |
Present study | 20 | II + III | 59.8 | 15 | 4 | LPFS 87.5% (24 months) |